Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans
暂无分享,去创建一个
C. Thorn | J. Christie | S E Kimmel | C Kealey | H Schelleman | C M Brensinger | M. Price | H. Schelleman | C. Brensinger | Zhen Chen | C F Thorn | J Chen | Z Chen | J Christie | C W Newcomb | M Price | A S Whitehead | F F Samaha | C F Thorn | C. Kealey | J. Chen | S. Kimmel | Z. Chen | CW Newcomb | AS Whitehead | FF Samaha | FF Samaha | Stephen E. Kimmel | Colleen M. Brensinger | Jinbo Chen | Jason D. Christie | Craig W. Newcomb | Alexander S. Whitehead | Caroline F. Thorn | Frederick F. Samaha | S. Kimmel
[1] P. Deloukas,et al. Association of warfarin dose with genes involved in its action and metabolism , 2006, Human Genetics.
[2] M. Margaglione,et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.
[3] Howard L McLeod,et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin , 2003, Thrombosis and Haemostasis.
[4] M. Margaglione,et al. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. , 2004, Haematologica.
[5] M. Caldwell,et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. , 2004, Pharmacogenetics.
[6] S. Fihn,et al. The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin , 1996, Annals of Internal Medicine.
[7] C. Thorn,et al. Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians , 2007, Clinical pharmacology and therapeutics.
[8] Peter Wood,et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.
[9] E. Hylek,et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. , 2005, Chest.
[10] M. Ritchie,et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.
[11] C. Thorn,et al. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. , 2007, Pharmacogenomics.
[12] V. Dolžan,et al. The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement , 2006, Thrombosis and Haemostasis.
[13] I. Ieiri,et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. , 2003, Blood.
[14] S. Hunt,et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.
[15] M. Rieder,et al. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.
[16] J. Goldstein,et al. Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. , 2007, Personalized medicine.
[17] Kevin Weiss,et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. , 2017, Annals of internal medicine.
[18] S. Moll,et al. Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants , 1998, Annals of Internal Medicine.
[19] D. Conrad,et al. A worldwide survey of haplotype variation and linkage disequilibrium in the human genome , 2006, Nature Genetics.
[20] K. Fahrbach,et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. , 2004, Chest.
[21] E. Lange,et al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation , 2006, Journal of Medical Genetics.
[22] C. Thorn,et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans , 2008, The Pharmacogenomics Journal.
[23] K. Klinger,et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. , 1993, Human molecular genetics.
[24] A. Wu,et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. , 2008, Pharmacogenomics.
[25] S. Thompson,et al. Factors affecting the maintenance dose of warfarin. , 1992, Journal of clinical pathology.
[26] G. Guyatt,et al. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy , 2004 .
[27] J. Hirsh,et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[28] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[29] J. Hirsh,et al. Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy , 1997, Annals of Internal Medicine.
[30] B. Horne,et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.
[31] T. Lindahl,et al. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records , 2006, Journal of thrombosis and haemostasis : JTH.
[32] Howard L McLeod,et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype , 2005, Thrombosis and Haemostasis.
[33] Deborah A. Nickerson,et al. Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans , 2003, Nature Genetics.
[34] Jon Emery,et al. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis , 2005, Genetics in Medicine.
[35] D. Cosh,et al. Prospective evaluation of a flexible protocol for starting treatment with warfarin and predicting its maintenance dose. , 1989, Australian and New Zealand journal of medicine.